Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

Virginia Pascual, Florence Allantaz, Edsel Arce et al. · The Journal of Experimental Medicine · 2005 · 917 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition

Raphaela Goldbach‐Mansky, Natalie Dailey Garnes, Scott Canna et al. · New England Journal of Medicine · 2006 · 903 citations · Full text

Medicine, Immunology, Pediatrics +17

Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

Peter A. Nigrović, Melissa L. Mannion, Femke H. M. Prince et al. · Arthritis & Rheumatism · 2010 · 464 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +10

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Thierry Lequerré, Pierre Quartier, David Rosellini et al. · Annals of the Rheumatic Diseases · 2007 · 404 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +11

The pattern of response to anti–interleukin‐1 treatment distinguishes two subsets of patients with systemic‐onset juvenile idiopathic arthritis

Marco Gattorno, Alessandra Piccini, Denise Lasigliè et al. · Arthritis & Rheumatism · 2008 · 380 citations

Life Sciences, Immunology, Pharmacotherapy +16